Ferriprox (deferiprone) — United Healthcare
Transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias
Initial criteria
- Diagnosis of transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias
- Ferriprox will not be used for the treatment of transfusional iron overload due to myelodysplastic syndrome or Diamond Blackfan anemia
Reauthorization criteria
- Documentation of positive clinical response to Ferriprox therapy
Approval duration
12 months